Growth Metrics

Alnylam Pharmaceuticals (ALNY) Short term Debt (2024 - 2025)

Alnylam Pharmaceuticals (ALNY) has disclosed Short term Debt for 2 consecutive years, with $121.3 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Short term Debt changed N/A year-over-year to $121.3 million, compared with a TTM value of $121.3 million through Sep 2025, changed N/A, and an annual FY2024 reading of $93.8 million, changed N/A over the prior year.
  • Short term Debt was $121.3 million for Q3 2025 at Alnylam Pharmaceuticals, roughly flat from $120.8 million in the prior quarter.
  • Across five years, Short term Debt topped out at $121.3 million in Q3 2025 and bottomed at $93.8 million in Q4 2024.